Patents by Inventor Terufumi Takagi
Terufumi Takagi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11197858Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: January 27, 2020Date of Patent: December 14, 2021Assignee: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
-
Patent number: 10800754Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: September 14, 2017Date of Patent: October 13, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Masato Yoshida, Shinichi Imamura
-
Patent number: 10774083Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: September 14, 2017Date of Patent: September 15, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Shinichi Imamura
-
Publication number: 20200230137Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: January 27, 2020Publication date: July 23, 2020Applicant: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
-
Patent number: 10696651Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: August 9, 2017Date of Patent: June 30, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Jun Fujimoto, Xin Liu, Osamu Kurasawa, Terufumi Takagi, Douglas Robert Cary, Hiroshi Banno, Yasutomi Asano, Takuto Kojima
-
Patent number: 10543212Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: March 23, 2018Date of Patent: January 28, 2020Assignee: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
-
Publication number: 20190359587Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: September 14, 2017Publication date: November 28, 2019Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takaharu HIRAYAMA, Yasuhiro HIRATA, Yusuke TOMINARI, Naoki IWAMURA, Yusuke SASAKI, Moriteru ASANO, Terufumi TAKAGI, Masanori OKANIWA, Masato YOSHIDA, Shinichi IMAMURA
-
Publication number: 20190241566Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: September 14, 2017Publication date: August 8, 2019Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takaharu HIRAYAMA, Yasuhiro HIRATA, Yusuke TOMINARI, Naoki IWAMURA, Yusuke SASAKI, Moriteru ASANO, Terufumi TAKAGI, Masanori OKANIWA, Masato YOSHIDA, Takashi ICHIKAWA, Shinichi IMAMURA
-
Publication number: 20190169166Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: August 9, 2017Publication date: June 6, 2019Applicant: Takeda Pharmaceutical Company LimitedInventors: Jun FUJIMOTO, Xin LIU, Osamu KURASAWA, Terufumi TAKAGI, Douglas Robert CARY, Hiroshi BANNO, Yasutomi ASANO, Takuto KOJIMA
-
Patent number: 10308605Abstract: A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof, or a prodrug therType: GrantFiled: August 1, 2014Date of Patent: June 4, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Atsushi Hasuoka, Naoki Tarui, Terufumi Takagi
-
Publication number: 20180280389Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: March 23, 2018Publication date: October 4, 2018Applicant: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
-
Patent number: 9890145Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: April 25, 2016Date of Patent: February 13, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Masato Yoshida, Kazuaki Takami, Yusuke Tominari, Zenyu Shiokawa, Akito Shibuya, Yusuke Sasaki, Tony Gibson, Terufumi Takagi
-
Publication number: 20160311811Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: April 25, 2016Publication date: October 27, 2016Applicant: Takeda Pharmaceutical Company LimitedInventors: Masato YOSHIDA, Kazuaki TAKAMI, Yusuke TOMINARI, Zenyu SHIOKAWA, Akito SHIBUYA, Yusuke SASAKI, Tony GIBSON, Terufumi TAKAGI
-
Patent number: 9321757Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: November 5, 2014Date of Patent: April 26, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Masato Yoshida, Kazuaki Takami, Yusuke Tominari, Zenyu Shiokawa, Akito Shibuya, Yusuke Sasaki, Tony Gibson, Terufumi Takagi
-
Publication number: 20150133451Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: November 5, 2014Publication date: May 14, 2015Applicant: Takeda Pharmaceutical Company LimitedInventors: Masato Yoshida, Kazuaki TAKAMI, Yusuke TOMINARI, Zenyu SHIOKAWA, Akito SHIBUYA, Yusuke SASAKI, Tony GIBSON, Terufumi TAKAGI
-
Publication number: 20140343070Abstract: A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof, or a prodrug theType: ApplicationFiled: August 1, 2014Publication date: November 20, 2014Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Masahiro Kajino, Atsushi Hasuoka, Naoki Tarui, Terufumi Takagi
-
Patent number: 8686010Abstract: The present invention provides a compound having a superior acid secretion inhibitory action, an antiulcer activity and the like.Type: GrantFiled: August 5, 2011Date of Patent: April 1, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Atsushi Hasuoka, Terufumi Takagi, Haruyuki Nishida
-
Patent number: 8497274Abstract: Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: GrantFiled: January 10, 2012Date of Patent: July 30, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Masanori Okaniwa, Terufumi Takagi, Masaaki Hirose
-
Patent number: 8344135Abstract: The present invention provides a heterocyclic compound having a strong Raf inhibitory activity, which is represented by the following formula wherein each substituent is as defined in the present specification, or a salt thereof.Type: GrantFiled: August 28, 2008Date of Patent: January 1, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Masaaki Hirose, Masanori Okaniwa, Yoko Hayashi, Terufumi Takagi
-
Publication number: 20120214855Abstract: Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: ApplicationFiled: January 10, 2012Publication date: August 23, 2012Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Masanori OKANIWA, Terufumi TAKAGI, Masaaki HIROSE